Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.

Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2 May 2005Cited by 141 (Europe PMC)

PMID16059622DOI10.1359/jbmr.050501PepBankPUB-16059622

Source link PubMedAsk about this study

Jump to 13 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study13

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In women followed after teriparatide, pooled former teriparatide groups had a fracture hazard ratio of 0.57 versus former placebo over 50 months.
In plain wordsIn women, former teriparatide groups had lower nonvertebral fragility fracture risk than former placebo over treatment and follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures over treatment and follow-up
Study
n = 1,262
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 and 40 microg pooled · subcutaneous · Median treatment exposure 19 months; 50-month period including follow-upAs given in this study (human).
Measurements
Hazard ratio
0.57 ratio
combined teriparatide versus placebo over 50 months
Source sentences
Summary
The hazard ratio for combined teriparatide group (20 and 40 microg) for the 50-month period after baseline was 0.57 (p = 0.002), suggesting a sustained effect in reducing the risk of nonvertebral fragility fracture.
3 context sentences(design, population, supporting numbers)
Summary · context
The hazard ratios for nonvertebral fragility fractures in each teriparatide group relative to placebo were statistically significant for the 50-month period including treatment and follow-up (p < 0.03).
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962201
02HumanObservational studyEfficacy outcome
In women, pooled former teriparatide groups had significantly lower fracture hazard during follow-up than former placebo.
In plain wordsIn women, pooled former teriparatide groups had lower fracture risk during follow-up than former placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures during follow-up
Study
n = 1,262
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 and 40 microg pooledAs given in this study (human).
Source sentences
Summary
In the follow-up period, the hazard ratio was significantly different between the 40 mug and combined groups versus placebo but not for the 20 microg group versus placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
While the study design is observational, the results support a sustained effect of teriparatide in reducing the risk of nonvertebral fragility fractures up to 30 months after discontinuation of treatment.
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962205
03HumanObservational studyEfficacy outcome
In women, fracture incidence in the former placebo and former teriparatide groups diverged over the 50-month period including treatment and follow-up.
In plain wordsIn women, fracture rates in the former teriparatide and former placebo groups moved apart over the 50 months of treatment and follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedTime to fracture
Study
n = 1,262
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 and 40 microg pooledAs given in this study (human).
Source sentences
Summary
Kaplan-Meier analysis of time to fracture showed that the fracture incidence in the former placebo and teriparatide groups diverged during the 50-month period including teriparatide treatment and follow-up (p = 0.009).
3 context sentences(design, population, supporting numbers)
Summary · context
While the study design is observational, the results support a sustained effect of teriparatide in reducing the risk of nonvertebral fragility fractures up to 30 months after discontinuation of treatment.
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962208
04HumanObservational studyEfficacy outcome
In women, the former teriparatide 20 microg group had significantly lower nonvertebral fragility fracture risk than former placebo over treatment and follow-up.
In plain wordsIn women, prior teriparatide treatment was linked to lower nonvertebral fragility fracture risk than prior placebo over treatment and follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures over treatment and follow-up
Study
n: not reported in source
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microg · subcutaneous · Median treatment exposure 19 months; 50-month period including follow-upAs given in this study (human).
Source sentences
Summary
The hazard ratios for nonvertebral fragility fractures in each teriparatide group relative to placebo were statistically significant for the 50-month period including treatment and follow-up (p < 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962202
05HumanObservational studyEfficacy outcome
In women, the former teriparatide 40 microg group had significantly lower nonvertebral fragility fracture risk than former placebo over treatment and follow-up.
In plain wordsIn women, prior teriparatide treatment was linked to lower nonvertebral fragility fracture risk than prior placebo over treatment and follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures over treatment and follow-up
Study
n: not reported in source
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous · Median treatment exposure 19 months; 50-month period including follow-upAs given in this study (human).
Source sentences
Summary
The hazard ratios for nonvertebral fragility fractures in each teriparatide group relative to placebo were statistically significant for the 50-month period including treatment and follow-up (p < 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962203
06HumanObservational studyEfficacy outcome
In women, fracture hazard during follow-up was significantly lower after teriparatide 40 microg than after placebo.
In plain wordsIn women, fracture risk during follow-up was lower after teriparatide than after placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseNonvertebral fragility fractures during follow-up
Study
n: not reported in source
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 microg · subcutaneous · Median treatment exposure 19 months; follow-up after discontinuationAs given in this study (human).
Source sentences
Summary
In the follow-up period, the hazard ratio was significantly different between the 40 mug and combined groups versus placebo but not for the 20 microg group versus placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
While the study design is observational, the results support a sustained effect of teriparatide in reducing the risk of nonvertebral fragility fractures up to 30 months after discontinuation of treatment.
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962204
07HumanObservational studyEfficacy outcome
In women, fracture hazard during follow-up did not differ significantly after teriparatide 20 microg versus placebo.
In plain wordsIn women, follow-up fracture risk did not differ significantly after teriparatide versus placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeNonvertebral fragility fractures during follow-up
Study
n: not reported in source
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microgAs given in this study (human).
Source sentences
Summary
In the follow-up period, the hazard ratio was significantly different between the 40 mug and combined groups versus placebo but not for the 20 microg group versus placebo.
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962206
08HumanObservational studyEfficacy outcome
In women, fracture hazard during follow-up did not differ between former teriparatide dose groups.
In plain wordsIn women, follow-up fracture risk did not differ between former teriparatide dose groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFracture hazard comparison between doses
Study
n: not reported in source
Comparator
40 microg teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 microgAs given in this study (human).
Source sentences
Summary
However, the 20 and 40 microg groups were not different from each other.
3 context sentences(design, population, supporting numbers)
Summary · context
In the follow-up period, the hazard ratio was significantly different between the 40 mug and combined groups versus placebo but not for the 20 microg group versus placebo.
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
Report a problemFND-1605962207

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

09HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In women after treatment withdrawal, osteoporosis treatment use was lower in the combined former teriparatide groups than in former placebo.
In plain wordsIn women after treatment withdrawal, osteoporosis treatment use was lower after teriparatide than after placebo.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseOsteoporosis treatment during follow-up
Study
n = 1,262
Comparator
Former placebo group
Outcome group
Bone and joint · Musculoskeletal
Measurements
Patients receiving osteoporosis treatment during follow-up
≈ 60%
all 1262 patients, overall
Source sentences
Summary
Approximately 60% of the 1262 patients received an osteoporosis treatment at some time during follow-up, with greater use in the former placebo group than in the combined former teriparatide group (p < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1605962213
10HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women without follow-up treatment, total hip BMD decreased after teriparatide withdrawal.
In plain wordsIn women without follow-up treatment, hip bone density decreased after teriparatide withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseTotal hip BMD after withdrawal without treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total hip and femoral neck BMD decreased in teriparatide-treated patients who had no follow-up treatment; BMD remained stable or further increased in patients who received a bisphosphonate after teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1605962209
11HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women without follow-up treatment, femoral neck BMD decreased after teriparatide withdrawal.
In plain wordsIn women without follow-up treatment, femoral neck bone density decreased after teriparatide withdrawal.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseFemoral neck BMD after withdrawal without treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total hip and femoral neck BMD decreased in teriparatide-treated patients who had no follow-up treatment; BMD remained stable or further increased in patients who received a bisphosphonate after teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1605962210
12HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving bisphosphonate after teriparatide, total hip BMD remained stable or increased further.
In plain wordsIn women, hip bone density stayed stable or increased with bisphosphonate after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedTotal hip BMD with subsequent bisphosphonate
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total hip and femoral neck BMD decreased in teriparatide-treated patients who had no follow-up treatment; BMD remained stable or further increased in patients who received a bisphosphonate after teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1605962211
13HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In women receiving bisphosphonate after teriparatide, femoral neck BMD remained stable or increased further.
In plain wordsIn women, femoral neck bone density stayed stable or increased with bisphosphonate after teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedFemoral neck BMD with subsequent bisphosphonate
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Total hip and femoral neck BMD decreased in teriparatide-treated patients who had no follow-up treatment; BMD remained stable or further increased in patients who received a bisphosphonate after teriparatide treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
A follow-up in 1262 women was conducted after the discontinuation of teriparatide.
Summary · context
Prior treatment assignments were revealed, and patients were able to receive osteoporosis treatments without restriction.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-1605962212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.